WO1997025429A1
(fr)
|
1996-01-04 |
1997-07-17 |
Rican Limited |
Bacterioferritine de helicobacter pilori
|
MXPA03003690A
(es)
|
2000-10-27 |
2004-05-05 |
Chiron Spa |
Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
|
ES2397627T3
(es)
|
2000-12-07 |
2013-03-08 |
Novartis Vaccines And Diagnostics, Inc. |
Retrovirus endógenos regulados por aumento en el cáncer de próstata
|
TWI228420B
(en)
*
|
2001-05-30 |
2005-03-01 |
Smithkline Beecham Pharma Gmbh |
Novel vaccine composition
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
US8481043B2
(en)
|
2001-06-22 |
2013-07-09 |
Cpex Pharmaceuticals, Inc. |
Nasal immunization
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
ES2607431T3
(es)
|
2002-02-20 |
2017-03-31 |
Glaxosmithkline Biologicals Sa |
Micropartículas con moléculas que contienen polipéptidos adsorbidos
|
CA2489292A1
(fr)
|
2002-06-13 |
2003-12-24 |
Chiron Corporation |
Vecteurs pour l'expression de polypeptides hml-2
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
HUE031886T2
(en)
|
2002-10-11 |
2017-08-28 |
Glaxosmithkline Biologicals Sa |
Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
|
AU2003288660A1
(en)
|
2002-11-15 |
2004-06-15 |
Chiron Srl |
Unexpected surface proteins in neisseria meningitidis
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
CA2511512C
(fr)
|
2002-12-27 |
2013-10-29 |
Chiron Corporation |
Immunogenes contenant des compositions de phospholipide
|
CA3042073C
(fr)
|
2003-01-30 |
2022-09-13 |
Novartis Vaccines And Diagnostics S.R.L. |
Vaccins injectables contre les multiples serogroupes du meningocoque
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
ES2529736T3
(es)
|
2003-04-10 |
2015-02-25 |
Novartis Vaccines And Diagnostics, Inc. |
Composición inmunogénica que comprende una proteína espicular del coronavirus del SARS
|
JP5557415B2
(ja)
|
2003-06-02 |
2014-07-23 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
吸着させたトキソイドおよび多糖類含有抗原を含む微粒子に基づく免疫原性組成物
|
US20060035242A1
(en)
|
2004-08-13 |
2006-02-16 |
Michelitsch Melissa D |
Prion-specific peptide reagents
|
CA2885040C
(fr)
|
2003-10-02 |
2018-10-30 |
Novartis Vaccines And Diagnostics S.R.L. |
Vaccins liquides contre de multiples serogroupes meningococciques
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
JP5600375B2
(ja)
|
2004-03-09 |
2014-10-01 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
インフルエンザウイルスワクチン
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
SI1740217T1
(sl)
|
2004-04-30 |
2011-10-28 |
Novartis Ag |
Konjugirano meningokokno cepljenje
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
WO2006078294A2
(fr)
|
2004-05-21 |
2006-07-27 |
Novartis Vaccines And Diagnostics Inc. |
Vecteurs d'alphavirus pour vaccins contre pathogenes respiratoires
|
CA2571421A1
(fr)
|
2004-06-24 |
2006-01-05 |
Nicholas Valiante |
Composes utilises pour l'immunopotentialisation
|
JP2008508320A
(ja)
|
2004-07-29 |
2008-03-21 |
カイロン コーポレイション |
Streptococcusagalactiaeのようなグラム陽性細菌に対する免疫原性組成物
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
PL2682126T3
(pl)
|
2005-01-27 |
2017-07-31 |
Children's Hospital & Research Center At Oakland |
Szczepionki pęcherzykowe oparte na GNA1870 dla szerokiego spektrum ochrony przeciwko chorobom spowodowanym przez Neisseria meningitidis
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
PL1858920T3
(pl)
|
2005-02-18 |
2016-12-30 |
|
Białka i kwasy nukleinowe z Escherichia coli związane z zapaleniem opon mózgowych/sepsą
|
NZ580974A
(en)
|
2005-02-18 |
2011-05-27 |
Novartis Vaccines & Diagnostic |
Immunogens from uropathogenic escherichia coli
|
US20090130127A1
(en)
|
2005-08-01 |
2009-05-21 |
Seiji Tokumoto |
Adjuvant or Pharmaceutical Preparation for Transdermal or Transmucousal Administration
|
US20110223197A1
(en)
|
2005-10-18 |
2011-09-15 |
Novartis Vaccines And Diagnostics Inc. |
Mucosal and Systemic Immunization with Alphavirus Replicon Particles
|
US11707520B2
(en)
|
2005-11-03 |
2023-07-25 |
Seqirus UK Limited |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
NZ567980A
(en)
*
|
2005-11-04 |
2012-01-12 |
Novartis Vaccines & Diagnostic |
Administration routes (intranasal or mucosal and parenteral or intramuscular) for priming/boosting with influenza vaccines
|
DK2368572T3
(da)
|
2005-11-04 |
2020-05-25 |
Seqirus Uk Ltd |
Adjuvansvacciner med ikke-virionantigener fremstillet fra influenza-virusser dyrket i cellekultur
|
ES2514316T3
(es)
|
2005-11-22 |
2014-10-28 |
Novartis Vaccines And Diagnostics, Inc. |
Partículas similares a virus (VLPs) de Norovirus y Sapovirus
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
CA2640248A1
(fr)
|
2006-01-27 |
2007-08-02 |
Novartis Vaccines And Diagnostics Gmbh & Co Kg. |
Vaccins contre la grippe contenant des hemaglutinines et des proteines matricielles
|
US8535683B2
(en)
|
2006-03-22 |
2013-09-17 |
Abbott Biologicals B.V. |
Intranasal or inhalational administration of virosomes
|
EP2010537B1
(fr)
|
2006-03-23 |
2011-12-28 |
Novartis AG |
Composés d'imidazoquinoxaline utilisés en tant qu'immunomodulateurs
|
US20100068223A1
(en)
|
2006-03-24 |
2010-03-18 |
Hanno Scheffczik |
Storage of Influenza Vaccines Without Refrigeration
|
WO2007126825A2
(fr)
|
2006-03-31 |
2007-11-08 |
Novartis Ag |
Immunisation mucosale et parentérale combinée contre le vih
|
PT2054431E
(pt)
|
2006-06-09 |
2011-11-03 |
Novartis Ag |
Confórmeros de adesinas bacterianas
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
JP2010500399A
(ja)
|
2006-08-16 |
2010-01-07 |
ノバルティス アーゲー |
尿路病原性大腸菌由来の免疫原
|
MX2009002408A
(es)
|
2006-09-11 |
2009-03-20 |
Novartis Ag |
Elaboracion de vacunas para el virus de la influenza sin utilizar huevos.
|
NZ577405A
(en)
|
2006-12-06 |
2012-08-31 |
Novartis Ag |
Vaccines including antigen from four strains of influenza virus
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
US20100047327A1
(en)
*
|
2007-01-31 |
2010-02-25 |
Tetsuji Kuwahara |
Adjuvant for Transdermal or Transmucosal Administration and Pharmaceutical Preparation Containing the Same
|
KR20100045437A
(ko)
|
2007-06-27 |
2010-05-03 |
노파르티스 아게 |
첨가물이 적은 인플루엔자 백신
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
EP3067048B1
(fr)
|
2007-12-07 |
2018-02-14 |
GlaxoSmithKline Biologicals SA |
Compositions d'induction des réponses immunitaires
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
PL2235046T3
(pl)
|
2007-12-21 |
2012-12-31 |
Novartis Ag |
Zmutowane formy streptolizyny O
|
BRPI0907843A2
(pt)
|
2008-02-21 |
2015-08-04 |
Novartis Ag |
Polipeptídeos de fhbp menigocócicos
|
CA2717870A1
(fr)
|
2008-03-10 |
2009-09-17 |
Children's Hospital & Research Center At Oakland |
Proteines chimeres de liaison du facteur h contenant un domaine b heterologue, et procedes d'utilisation associes
|
EP2376108B1
(fr)
|
2008-12-09 |
2017-02-22 |
Pfizer Vaccines LLC |
Vaccin peptidique de ige ch3
|
MX2011007456A
(es)
|
2009-01-12 |
2011-08-03 |
Novartis Ag |
Antigenos del dominio de proteina de superficie de union a colageno tipo b (can_b) en vacunas contra bacteria gram positiva.
|
JP5642712B2
(ja)
|
2009-02-10 |
2014-12-17 |
ノバルティス アーゲー |
少ない量のスクアレンを含むインフルエンザワクチン
|
EP2403526B1
(fr)
|
2009-03-06 |
2019-05-15 |
GlaxoSmithKline Biologicals SA |
Antigènes de chlamydia
|
CA3154626A1
(fr)
|
2009-04-14 |
2010-10-21 |
Glaxosmithkline Biologicals S.A. |
Compositions pour l'immunisation contre le staphylococcus aureus
|
BRPI1014494A2
(pt)
|
2009-04-30 |
2016-08-02 |
Coley Pharm Group Inc |
vacina pneumocócica e usos da mesma
|
WO2010146414A1
(fr)
|
2009-06-15 |
2010-12-23 |
National University Of Singapore |
Vaccin contre l'influenza, composition, et procedes d'utilisation
|
CA2767536A1
(fr)
|
2009-07-07 |
2011-01-13 |
Novartis Ag |
Immunogenes d' escherichia coli conserves
|
RU2585227C2
(ru)
|
2009-07-15 |
2016-05-27 |
Новартис Аг |
Композиции белка f rsv и способы их получения
|
JP2012532626A
(ja)
|
2009-07-16 |
2012-12-20 |
ノバルティス アーゲー |
無毒化されたEscherichiacoli免疫原
|
CN102596236B
(zh)
|
2009-07-30 |
2015-06-24 |
辉瑞疫苗有限责任公司 |
抗原性Tau肽及其用途
|
WO2011024072A2
(fr)
|
2009-08-27 |
2011-03-03 |
Novartis Ag |
Polypeptides hybrides contenant des séquences fhbp à méningocoques
|
SG10201401516XA
(en)
|
2009-09-03 |
2014-10-30 |
Pfizer Vaccines Llc |
Pcsk9 vaccine
|
WO2011138636A1
(fr)
|
2009-09-30 |
2011-11-10 |
Novartis Ag |
Conjugaison de polysaccharides capsulaires de staphylococcus aureus de type 5 et de type 8
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
JP5960055B2
(ja)
|
2009-10-27 |
2016-08-02 |
ノバルティス アーゲー |
改変髄膜炎菌fHBPポリペプチド
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
RU2581020C2
(ru)
|
2009-12-22 |
2016-04-10 |
Селлдекс Терапьютикс, Инк. |
Композиции вакцин
|
US9173954B2
(en)
|
2009-12-30 |
2015-11-03 |
Glaxosmithkline Biologicals Sa |
Polysaccharide immunogens conjugated to E. coli carrier proteins
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
AU2011238670B2
(en)
|
2010-03-30 |
2015-04-23 |
Children's Hospital & Research Center Oakland |
Factor H binding proteins (FHBP) with altered properties and methods of use thereof
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
EP2558069A1
(fr)
|
2010-04-13 |
2013-02-20 |
Novartis AG |
Compositions de benzonapthyridine et leurs utilisations
|
CN102933267B
(zh)
|
2010-05-28 |
2015-05-27 |
泰特里斯在线公司 |
交互式混合异步计算机游戏基础结构
|
CA2800774A1
(fr)
|
2010-06-07 |
2011-12-15 |
Pfizer Vaccines Llc |
Vaccin peptidique ige ch3
|
CA2798837A1
(fr)
|
2010-06-07 |
2011-12-15 |
Pfizer Inc. |
Peptides her-2 et vaccins
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
JP2013533745A
(ja)
|
2010-07-06 |
2013-08-29 |
ノバルティス アーゲー |
ノロウイルスに由来する免疫原性組成物および方法
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
WO2012072769A1
(fr)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Epitopes rrgb de pneumocoque et combinaisons de variantes
|
US20130315959A1
(en)
|
2010-12-24 |
2013-11-28 |
Novartis Ag |
Compounds
|
PL2667892T3
(pl)
|
2011-01-26 |
2019-09-30 |
Glaxosmithkline Biologicals Sa |
Schemat szczepień przeciwko rsv
|
US20140004142A1
(en)
|
2011-03-02 |
2014-01-02 |
Pfizer Inc. |
Pcsk9 vaccine
|
JP2014519819A
(ja)
|
2011-05-13 |
2014-08-21 |
ノバルティス アーゲー |
融合前rsvf抗原
|
JP2014522842A
(ja)
|
2011-07-06 |
2014-09-08 |
ノバルティス アーゲー |
免疫原性組み合わせ組成物およびその使用
|
EP2729168A2
(fr)
|
2011-07-06 |
2014-05-14 |
Novartis AG |
Compositions immunogènes et leurs utilisations
|
US10030052B2
(en)
|
2011-07-25 |
2018-07-24 |
Glaxosmithkline Biologicals Sa |
Parvovirus Vp1 unique region polypeptides and compositions thereof
|
EP2659906A1
(fr)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP2659908A1
(fr)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP2659907A1
(fr)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
SG10201603896RA
(en)
|
2012-05-04 |
2016-07-28 |
Pfizer |
Prostate-associated antigens and vaccine-based immunotherapy regimens
|
MX2014014067A
(es)
|
2012-05-22 |
2015-02-04 |
Novartis Ag |
Conjugado de serogrupo x de meningococo.
|
US20150140068A1
(en)
|
2012-07-06 |
2015-05-21 |
Novartis Ag |
Immunogenic compositions and uses thereof
|
MX2015004171A
(es)
|
2012-10-02 |
2015-10-22 |
Glaxosmithkline Biolog Sa |
Conjugados de sacaridos no lineales.
|
SG11201500978TA
(en)
|
2012-10-03 |
2015-07-30 |
Glaxosmithkline Biolog Sa |
Immunogenic compositions
|
WO2014083060A2
(fr)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Antigènes et combinaisons d'antigènes de pseudomonas
|
EP2996718B1
(fr)
|
2013-05-15 |
2020-01-15 |
The Governors of the University of Alberta |
Vaccins contre le vhc e1e2 et procédés d'utilisation desdits vaccins
|
US9993549B2
(en)
|
2013-10-31 |
2018-06-12 |
Hisamitsu Pharmaceutical Co., Inc. |
Adjuvant composition, adjuvant preparation containing same, and kit
|
KR20220080201A
(ko)
|
2014-01-21 |
2022-06-14 |
화이자 인코포레이티드 |
접합된 캡슐 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2015123291A1
(fr)
|
2014-02-11 |
2015-08-20 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Vaccin à base de pcsk9 et méthodes d'utilisation dudit vaccin
|
KR20170028442A
(ko)
|
2014-07-23 |
2017-03-13 |
칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 |
인자 h 결합 단백질 변이체 및 이의 사용 방법
|
KR102149760B1
(ko)
|
2015-01-15 |
2020-08-31 |
화이자 인코포레이티드 |
폐렴구균 백신에서 사용하기 위한 면역원성 조성물
|
WO2016193405A1
(fr)
|
2015-06-03 |
2016-12-08 |
Affiris Ag |
Vaccins d'il-23-p19
|
AU2016289497A1
(en)
|
2015-07-07 |
2017-12-07 |
Affiris Ag |
Vaccines for the treatment and prevention of IgE mediated diseases
|
TWI684461B
(zh)
|
2015-07-21 |
2020-02-11 |
美商輝瑞股份有限公司 |
包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途
|
CA3005524C
(fr)
|
2015-11-20 |
2023-10-10 |
Pfizer Inc. |
Compositions immunogenes destinees a etre utilisees dans des vaccins pneumococciques
|
EP3733201A1
(fr)
|
2016-01-19 |
2020-11-04 |
Pfizer Inc |
Vaccins contre le cancer
|
RU2762723C2
(ru)
|
2017-01-20 |
2021-12-22 |
Пфайзер Инк. |
Иммуногенные композиции для применения в пневмококковых вакцинах
|
WO2019173438A1
(fr)
|
2018-03-06 |
2019-09-12 |
Stc. Unm |
Compositions et méthodes pour faire baisser les triglycérides sériques
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
CA3120922A1
(fr)
|
2018-12-12 |
2020-06-18 |
Pfizer Inc. |
Conjugues polysaccharide-proteine immunogenes a heteroantigenes multiples et leurs utilisations
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
US20220184199A1
(en)
|
2019-04-10 |
2022-06-16 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
EP4051696A1
(fr)
|
2019-11-01 |
2022-09-07 |
Pfizer Inc. |
Compositions d'escherichia coli et méthodes associées
|
MX2022010355A
(es)
|
2020-02-21 |
2022-09-21 |
Pfizer |
Purificacion de sacaridos.
|
AU2021223184A1
(en)
|
2020-02-23 |
2022-08-18 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
CN115175924A
(zh)
|
2020-02-26 |
2022-10-11 |
港大科桥有限公司 |
基于pd-1的针对冠状病毒感染的疫苗
|
CA3199610A1
(fr)
|
2020-10-27 |
2022-05-05 |
Pfizer Inc. |
Compositions d'escherichia coli et procedes associes
|
US20240000912A1
(en)
|
2020-11-04 |
2024-01-04 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
EP4243863A2
(fr)
|
2020-11-10 |
2023-09-20 |
Pfizer Inc. |
Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
|
TWI750929B
(zh)
*
|
2020-12-02 |
2021-12-21 |
林建宏 |
氣霧免疫用之溫敏型佐劑及其製作方法
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
WO2022147373A1
(fr)
|
2020-12-31 |
2022-07-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Immunogènes imitant la pcsk9 guidés par des anticorps et ne présentant pas de chevauchement de séquence de 9 résidus avec des protéines humaines
|
AU2022223712A1
(en)
|
2021-02-19 |
2023-10-05 |
Sanofi Pasteur Inc. |
Meningococcal b recombinant vaccine
|
EP4333868A1
(fr)
|
2021-05-04 |
2024-03-13 |
King Abdullah University Of Science And Technology |
Compositions immuogéniques de protéine n mutante de sars-cov-2 et gène et procédés d'utilisation associés
|
TW202306969A
(zh)
|
2021-05-28 |
2023-02-16 |
美商輝瑞大藥廠 |
包含結合之莢膜醣抗原的免疫原組合物及其用途
|
US20220387613A1
(en)
|
2021-05-28 |
2022-12-08 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2023079528A1
(fr)
|
2021-11-05 |
2023-05-11 |
King Abdullah University Of Science And Technology |
Compositions appropriées pour une utilisation dans un procédé pour déclencher une immunité protectrice croisée contre des coronavirus
|
WO2023079529A1
(fr)
|
2021-11-05 |
2023-05-11 |
King Abdullah University Of Science And Technology |
Compositions d'immunisation de rappel de protéine de refocalisation et leurs méthodes d'utilisation
|
CN118434441A
(zh)
|
2021-11-18 |
2024-08-02 |
马特里瓦克斯公司 |
免疫原性融合蛋白组合物和其使用方法
|
WO2023135515A1
(fr)
|
2022-01-13 |
2023-07-20 |
Pfizer Inc. |
Compositions immunogènes à base d'antigènes saccharidiques capsulaires conjugués et leurs utilisations
|
WO2023161817A1
(fr)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Procédés d'incorporation de groupes azido dans des polysaccharides capsulaires bactériens
|
WO2023218322A1
(fr)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Procédé de production de formulations de vaccin avec des conservateurs
|
WO2024018061A1
(fr)
|
2022-07-22 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Utilisation de souches de bordetella pour le traitement de la bronchopneumopathie chronique obstructive
|
WO2024110827A1
(fr)
|
2022-11-21 |
2024-05-30 |
Pfizer Inc. |
Procédés de préparation d'antigènes saccharidiques capsulaires conjugués et leurs utilisations
|
US20240181028A1
(en)
|
2022-11-22 |
2024-06-06 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2024116096A1
(fr)
|
2022-12-01 |
2024-06-06 |
Pfizer Inc. |
Formulations de vaccin pneumococcique conjugué
|
WO2024130009A1
(fr)
|
2022-12-14 |
2024-06-20 |
Yale University |
Compositions et leurs procédés d'utilisation pour le traitement de cancers entraînés par un virus
|
WO2024166008A1
(fr)
|
2023-02-10 |
2024-08-15 |
Pfizer Inc. |
Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
|